MedTrace Logo

A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease

NCT04312659 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2025-04-27

No results posted yet for this study

Summary

The main purpose of this study is to record the use of Infliximab (IFX) in the treatment of Chinese children with Crohn's disease (CD) in routine clinical practice and to summarize the clinical efficacy and safety of IFX in the treatment of pediatric CD.

Conditions

  • Crohn Disease

Interventions

DRUG

Infliximab

Participants will be observed who were treated with Infliximab.

Sponsors & Collaborators

  • Johnson & Johnson (China) Investment Ltd.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson (China) Investment Ltd. Clinical Trial · Johnson & Johnson (China) Investment Ltd.

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-15
Primary Completion
2023-09-12
Completion
2023-09-12

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04312659 on ClinicalTrials.gov